Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: A long-term extension study (CHEST-2)

European Respiratory Journal

Volumn 45, Issue 5, 2015, Pages 1293-1302

  Simonneau, Gérald ^a   D'Armini, Andrea M ^b   Ghofrani, Hossein Ardeschir ^c,d,e   Grimminger, Friedrich ^c,d   Hoeper, Marius M ^d,f   Jansa, Pavel ^g   Kim, Nick H ^h   Wang, Chen ⁱ   Wilkins, Martin R ^j   Fritsch, Arno ^k   Davie, Neil ^k   Colorado, Pablo ^l   Mayer, Eckhard ^m  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b UNIVERSITY OF PAVIA   (Italy)

^c JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

^d German Center of Lung Research (DZL)   (Germany)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f HANNOVER MEDICAL SCHOOL   (Germany)

^g CHARLES UNIVERSITY   (Czech Republic)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ CAPITAL MEDICAL UNIVERSITY   (China)

^j The National Institute for Health Research Health Protection Research Unit in Blood Borne and Sexually Transmitted Infections at University College London in partnership with UK Health Security Agency   (United Kingdom)

^k BAYER PHARMA AG   (Germany)

^l NONE   (Spain)

^m MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; RIOCIGUAT; ANTIHYPERTENSIVE AGENT; GUANYLATE CYCLASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONTROLLED STUDY; COUGHING; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; EXERCISE TEST; FAINTNESS; FEMALE; FUNCTIONAL STATUS; HEMOPTYSIS; HUMAN; HYPOTENSION; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIX MINUTE WALKING DISTANCE TEST; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; HYPERTENSION, PULMONARY; LUNG FUNCTION TEST; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK; THROMBOEMBOLISM; TIME FACTOR; WALKING;

AGED; ANTIHYPERTENSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; GUANYLATE CYCLASE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PYRAZOLES; PYRIMIDINES; RESPIRATORY FUNCTION TESTS; RISK; THROMBOEMBOLISM; TIME FACTORS; WALKING;

EID: 84929011910     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00087114     Document Type: Article

References (23)

1. Lang IM, Klepetko W. Chronic thromboembolic pulmonary hypertension: An updated review. Curr Opin Cardiol 2008; 23: 555-559.
2. Peacock A, Simonneau G, Rubin L. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc 2006; 3: 608-614.
3. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54: Suppl., S43-S54.
4. Kim NH, Delcroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62: Suppl., D92-D99.
5. Freed DH, Thomson BM, Berman M, et al. Survival after pulmonary thromboendarterectomy: Effect of residual pulmonary hypertension. J Thorac Cardiovasc Surg 2011; 141: 383-387.
6. Lang IM. Managing chronic thromboembolic pulmonary hypertension: pharmacological treatment options. Eur Respir Rev 2009; 18: 24-28.
7. Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 2011; 141: 702-710.
8. Wilkens H, Lang I, Behr J, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol 2011; 154: Suppl. 1, S54-S60.
9. Klinger JR. The nitric oxide/cGMP signaling pathway in pulmonary hypertension. Clin Chest Med 2007; 28: 143-167.
10. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 2011; 123: 2263-2273.
11. Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol 2013; 218: 279-313.
12. Follmann M, Griebenow N, Hahn MG, et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl 2013; 52: 9442-9462.
13. Schermuly RT, Janssen W, Weissmann N, et al. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs 2011; 20: 567-576.
14. Ghofrani HA, Galiè N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 2013; 369: 330-340.
15. Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319-329.
16. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013; 62: Suppl., D60-D72.
17. Simonneau G, Delcroix M, Lang IM, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: results of an international prospective registry comparing operated versus non operated patients. Am J Respir Crit Care Med 2013; 187: A5365.
18. Reesink HJ, van Delden OM, Kloek JJ, et al. Embolization for hemoptysis in chronic thromboembolic pulmonary hypertension: report of two cases and a review of the literature. Cardiovasc Intervent Radiol 2007; 30: 136-139.
19. Lang IM, Simonneau G, Pepke-Zaba JW, et al. Factors associated with diagnosis and operability of chronic thromboembolic pulmonary hypertension. A case-control study. Thromb Haemost 2013; 110: 83-91.
20. Henkens IR, Hazenoot T, Boonstra A, et al. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J 2013; 41: 872-878.
21. Tio D, Leter E, Boerrigter B, et al. Risk factors for hemoptysis in idiopathic and hereditary pulmonary arterial hypertension. PLoS One 2013; 8: E78132.
22. Fadel E, Wijtenburg E, Michel R, et al. Regression of the systemic vasculature to the lung after removal of pulmonary artery obstruction. Am J Respir Crit Care Med 2006; 173: 345-349.
23. Zylkowska J, Kurzyna M, Pietura R, et al. Recurrent hemoptysis: An emerging life-threatening complication in idiopathic pulmonary arterial hypertension. Chest 2011; 139: 690-693.